18 October 2019 | News
The facility was inspected by the USFDA between August 5, 2019 and August 8, 2019
Lupin has announced the receipt of the Establishment Inspection Report (EIR) from the USFDA for its Nagpur facility.
The facility was inspected by the USFDA between August 5, 2019 and August 8, 2019. The inspection for the oral solid facility at Nagpur closed without any Form 483 observation.
Commenting on the receipt of the EIR, Nilesh Gupta, Managing Director, Lupin said, “Excelling at Quality and Compliance is one of our top priorities and we remain committed to meeting and exceeding standards set by regulatory agencies globally.”
The Nagpur facility is Lupin’s largest and most advanced oral solid dosage facility and has maintained a solid track record of compliance.